Innova Captab

Innova Captab ROCE

The Return on Capital Employed (ROCE) of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 15.09 %. In the previous year, Return on Capital Employed (ROCE) was 32.60 % — a change of -53.71% (lower).

ROCE

15.09 %

YoY

-53.71%

Last updated:

In 2026, Innova Captab's return on capital employed (ROCE) was 15.09 %, a -53.71% increase from the 32.60 % ROCE in the previous year.

The Innova Captab ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
177.00 INR
Jan 1, 2020
17.80 INR
Jan 1, 2021
33.25 INR
Jan 1, 2022
42.51 INR
Jan 1, 2023
31.73 INR
Jan 1, 2024
16.68 INR
Jan 1, 2025
32.60 INR
Jan 1, 2026
15.09 INR
The Innova Captab ROCE history
YEARROCEYoY
15.09 %-53.71%
32.60 %+95.47%
16.68 %-47.43%
31.73 %-25.36%
42.51 %+27.87%
33.25 %+86.83%
17.80 %-89.95%
177.00 %+172.42%
64.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Innova Captab's Return on Capital Employed (ROCE)

Innova Captab's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Innova Captab's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Innova Captab's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Innova Captab’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Innova Captab stock

Return on Capital Employed (ROCE) of Innova Captab is 15.09 % in 2026.

Return on Capital Employed (ROCE) of Innova Captab changed from 32.60 % to 15.09 %, representing a -53.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Innova Captab since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Innova Captab with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Innova Captab

All Key Metrics — Innova Captab